• In the hypothetical health plan (100,000 members), ~0.54% (539) of members were estimated to be diagnosed with EAPP and receiving medical intervention.
• The total budget for treating EAPP in the hypothetical population of 100,000 in 2010 is estimated at €558,443, with €402,034 used for drug costs and €156,409 for resource costs (Table 4 ).
• Extrapolating these results to the total German population estimated at 81.9 million (41.7 million women) yields an overall EAPP population of 441,000 women in Germany.
• The estimated budget for treating EAPP is €452.9 million in Germany in 2010.
• By 2015, without the introduction of dienogest, the budget is expected to increase to €552,338 due to changes in the German population.
• If dienogest is introduced, the total budget is estimated to decrease by €61,790 by 2015.
• By year 5 the introduction of dienogest could save €4.98 million.
Treatment Costs
• The BIM considers the annual treatment costs associated with each of the comparative endometriosis treatments. The comparative treatments include all the different GnRH-a agents indicated (Table 2) . Hormone replacement therapy (tibolone) and combination OCs are included because they are associated with GnRH-a treatment.
• The average annual patient cost has been estimated from the average annual treatment duration for a woman on treatment over a 2-year period, which was derived from a recently developed CE model evaluating dienogest compared with a GnRH-a.
• In any given year, the number of women receiving treatment for a given therapy will consist of women who:
-Are new to the treatment at some point in the year -Continue to take the medication during the year and were on treatment in the previous year -Have taken the medication at some period during the year but are no longer doing so • Using this average treatment duration assumption allows us to take a snapshot of the patient mix and provide an estimate of the annual average treatment cost for a given therapy.
• Costs include the drug, administration, and resource costs.
• The CE model results showed that women treated with dienogest were on treatment for an average of 36.8 weeks per year compared with 29.6 weeks for women treated with a GnRH-a alone or 33.2 weeks for women treated with a GnRH-a and add-back therapy.
• Women on dienogest were assumed to receive a gynaecologist consultation every 3 months, whereas women on GnRH-a received monthly gynaecologist visits while on treatment but reverted to 3 monthly general practitioner visits while receiving maintenance therapy.
• Women on a GnRH-a also received an initial outpatient visit (Table 3) . For dienogest, different pricing scenarios were evaluated.
Introduction
• Endometriosis, characterised by the presence of endometrial-like tissue outside the uterus, is a chronic, complex, yet relatively common gynaecological disorder, affecting > 70 million females worldwide.
• Patients with endometriosis present with a variety of symptoms (e.g., chronic pelvic pain, dysmenorrhoea, and dyspareunia).
• Prevalence of endometriosis is reported as between 5% and 10% of the female population. [1] [2] [3] [4] • Dienogest is considered an advanced medical therapy for women who have not adequately responded to other medical treatment, including nonspecific pain treatment (nonsteroidal anti-inflammatory drugs) and oral contraceptives (OCs).
• The primary comparator for dienogest is the class of drugs known as gonadotropin-releasing hormone analogues (GnRH-a), which are considered the gold standard therapy for women with endometriosisassociated pelvic pain (EAPP).
• However, treatment with GnRH-a is associated with serious side effects such as decreasing bone mineral density and vasomotor symptoms; therefore, it may only be administered for a maximum of 6 months.
• A 12-month treatment with GnRH-a is only indicated with an appropriate add-back therapy (i.e., giving an additional drug to suppress the side effects). 5
• Following cessation of GnRH-a treatment, women are recommended to take maintenance therapy such as an OC. 6
Objective
• To evaluate the budget impact to a health plan after introducing dienogest (2 mg) as a treatment option at the expense of GnRH-a treatment for patients with EAPP
Methods
• The analysis was conducted from a German payer's perspective over a 5-year time horizon.
• The budget impact model (BIM) specifically considered women with EAPP, including women with newly diagnosed endometriosis and women in whom other previous medical treatment for EAPP failed.
• A recently developed cost-effectiveness (CE) model for endometriosis provided estimates of average treatment duration.
• This CE model compared different treatment pathways for women with EAPP and used a 50% improvement in pelvic pain as a definition of a treatment responder to elicit treatment duration.
• After combining epidemiologic data, market uptake assumptions from market research forecasting, current GnRH-a drug treatment costs, and average treatment duration, the BIM estimated the incremental budget impact after adopting dienogest as a treatment option at the expense of GnRH-a.
• The model assumed that during the first year 5% of patients with EAPP receive dienogest at the expense of GnRH-a. After 5 years, it was assumed that dienogest would capture 15% of the EAPP market (Table 1) .
Epidemiology
• A United Kingdom (UK) survey of women in 2001 found that 24.0% of women aged 18 to 49 years had chronic pelvic pain, excluding women with ovulation pain. 7
• Zondervan and colleagues 7 found that only one-quarter of women with chronic pelvic pain had sought medical advice in the previous year, implying an annual prevalence in primary care of 5.7%.
• Guo and Wang, 8 reviewed studies of endometriosis in women with chronic pelvic pain published between 1990 and 2008 and reported an average prevalence of 44.6% (19.7%-82.1%).
• Using estimates of the female German population from the German Federal Statistical Office publications, we derived an estimate of the number of women with EAPP seeking medical treatment (Figure 1 ). Women with EAPP seeking treatment = 539
Current Market Share
• An estimate of the 2010 market share of various GnRH-a comparator treatments for EAPP was derived using the number of drug items prescribed for endometriosis from the medical index data from IMS Health for 2007 using the N80 ICD-10 code for endometriosis (baseline) ( Table 1) . 
Conclusions
• The average patient treatment costs of dienogest are lower than for GnRH-a.
• The total budget reduction of a hypothetical health plan administrator, with a 100,000 population, is estimated at 1.1% based on dienogest capturing 15% of the GnRH-a market share (by 2015).
• Extrapolating these results to the total German population yields an overall estimated budget of €452.9 million for treating EAPP. Introducing dienogest could save €4.98 million by year 5.
